Hormonal
Systemic and hepatic insulin resistance is the central pathophysiological mechanism driving the development and progression of metabolic dysfunction-associated fatty liver disease (MAFLD).
Focus on improving insulin sensitivity through weight management, physical activity, and dietary quality. Since insulin resistance is the root cause of MAFLD, interventions that lower insulin levels and improve glucose handling (like exercise and reducing refined carbohydrates) are the most effective way to prevent or reverse liver fat accumulation.
Metabolic dysfunction in this context encompasses obesity, type 2 diabetes mellitus, hypertension, dyslipidemia, and metabolic syndrome, with insulin resistance as the common underlying pathophysiology.
Why this rating
This is a comprehensive review citing multiple meta-analyses, genome-wide association studies, and mechanistic animal/human studies.
Source
Role of Insulin Resistance in MAFLD
Yoshitaka Sakurai et al. · International Journal of Molecular Sciences · 2021
DOI 10.3390/ijms22084156
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →